Evidence map›Paper›PMID 41438993›Full record

ArticleFrontiers in oncology2025

Case Report: Successful management of high-volume paclitaxel extravasation with hyaluronidase and dry warm compresses.

Boris Dudík, Maroš Kunderlík, Bela Mriňáková, Zuzana Lukáčová, Vanda Ušáková, Ján Klimas

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Boris DudíkPharmacy of St. Elisabeth, St. Elisabeth Cancer Institute, Bratislava, Slovakia.
Maroš Kunderlík1st Department of Oncology, Faculty of Medicine, Comenius University Bratislava and St. Elisabeth Cancer Institute, Bratislava, Slovakia.
Bela Mriňáková1st Department of Oncology, Faculty of Medicine, Comenius University Bratislava and St. Elisabeth Cancer Institute, Bratislava, Slovakia.
Zuzana Lukáčová1st Department of Oncology, Faculty of Medicine, Comenius University Bratislava and St. Elisabeth Cancer Institute, Bratislava, Slovakia.
Vanda Ušáková1st Department of Oncology, Faculty of Medicine, Comenius University Bratislava and St. Elisabeth Cancer Institute, Bratislava, Slovakia.
Ján KlimasDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Paclitaxel is a widely used chemotherapeutic agent with known vesicant properties. Extravasation is rare, but it can result in significant local tissue injury. There is no consensus on the optimal management strategy, and recommendations differ significantly. Case presentation: We report the case of a 63-year-old woman with metastatic cervical cancer who experienced a large-volume paclitaxel extravasation during a peripheral infusion. Management involved immediate subcutaneous administration of hyaluronidase around the affected area, followed by repeated applications of dry warm compresses. The patient reported only mild discomfort during treatment, and the local cutaneous symptoms resolved within days. Despite effective local management, the patient developed persistent paresthesia in the extravasated limb, later diagnosed as sensory neuropathy affecting the ulnar nerve. This was accompanied by lower limb neuropathy, likely related to the systemic paclitaxel exposure. Paclitaxel was discontinued, and the patient continued palliative treatment with carboplatin monotherapy. Conclusion: Based on our literature search, this appears to be the first documented case of high-volume paclitaxel extravasation successfully managed with both hyaluronidase and dry warmth. The intervention proved to be effective in preventing severe local tissue injury, although it did not mitigate neurotoxic effects. Further research is needed to establish standardized management protocols.

Indexed as

extravasationhyaluronidasepaclitaxelvesicantswarm compresses

Identifiers

PMID41438993
PMCPMC12719265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.